Gamida Cell is pioneering next-generation cell therapies for patients with cancer and other serious diseases. We harness our diverse cellular therapy approach to create treatments with the potential to redefine standards of care in areas of serious medical need.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $107.9M
Founded date: 1998
Investors 6
| Date | Name | Website |
| - | Auriga Par... | auriga.vc |
| - | Shavit Cap... | shavitcapi... |
| - | Israel Bio... | ibf.fund |
| - | Access Bio... | accessbio-... |
| - | Israel Hea... | ihcv.co.il... |
| - | Arc Ventur... | arc-vc.com |
Funding Rounds 6
| Date | Series | Amount | Investors |
| 20.07.2017 | Grant | $3.5M | - |
| 19.06.2017 | - | $40M | - |
| 23.05.2016 | Grant | $4.4M | - |
| 12.10.2015 | - | $15M | - |
| 22.08.2014 | - | $35M | - |
| 15.05.2012 | Series E | $10M | - |
Mentions in press and media 14
| Date | Title | Description |
| 15.11.2021 | Gamida Cell : Reports Third Quarter 2021 Financial Results and Provides Company Update - Form 6-K | Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update ● New data being presented at American Society of Hematology (ASH) Annual Meeting demonstrating GDA-201 overall survival rate of 78% at two years with a me... |
| 26.10.2021 | Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today's Virtual R&D Day - Form 6-K | Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today's Virtual R&D Day ● Company recently filed an IND application for GDA-201; FDA placed the application on Clinical Hold pend... |
| 27.04.2018 | Ex-AstraZeneca exec Lisa Anson to lead do-over at Redx; Advaxis shakes up C-suite | Lisa Anson → Redx $REDX has enlisted esteemed British exec Lisa Anson to lead the company’s do-over as its CEO. Having held management roles at AstraZeneca for 20 years — serving as AstraZeneca UK’s president for the last si... |
| 20.07.2017 | Gamida Cell Receives $3.5M Grant | Gamida Cell, a Jerusalem, Israel-based provider of cellular and immune therapies for the treatment of cancer and orphan genetic diseases, has been awarded a grant of $3.5m from the Israel Innovation Authority (IIA) of the Israeli Ministry o... |
| 19.06.2017 | Term Sheet — Monday, June 19 | A DECLARATION OF WAR Good morning. I’m back and still digesting Friday’s Amazon-Whole Foods news. (Nothing like a bombshell deal announcement on a summer Friday when I happen to be out of the office! Thanks again to Anne for filling in for ... |
| 19.06.2017 | Gamida Cell Closes $40M Financing | Gamida Cell Ltd., a Jerusalem, Israel-based developer of cellular and immune therapies for the treatment of cancer and orphan genetic diseases, signed a $40m financing. The round is being led by new investor Shavit Capital with participatio... |
| 19.06.2017 | Gamida Cell $40MM Financing to support its Phase 3 Trial | Israel Biotech Fund participated in Gamida Cell’s $40MM financing round which shall support the ongoing Phase 3 trial of the its FDA Breakthrough Designated clinical-stage product, NiCord, to facilitate bone marrow transplantation. Read the... |
| 11.10.2016 | Novartis-backed Gamida Cell grabs a breakthrough trophy for experimental cell treatment | Israel’s Gamida Cell is getting flagged to the inside regulatory track at the FDA. The agency has handed the company – which includes Novartis as a prominent investor – its breakthrough drug designation for a top produc... |
| 23.05.2016 | Cancer Immune Therapy Developer Gamida Cell Receives up to $4.4M Grant | Gamida Cell, a Jerusalem, Israel-based developer of cellular and immune therapies for the treatment of cancer and orphan genetic diseases, received a grant of up to $4.4m. The Israel Innovation Authority (formerly the Office of the Chief Sc... |
| 25.10.2015 | Israeli Health Tech Is Heating Up With A Wave Of Interest From Abroad | Dennis Mitzner Contributor Dennis Mitzner is a journalist and writer with a focus on tech, culture and politics. You can find his commentary here. He also writes about e-commerce and retail for Forbes. More posts by this contributor Magic L... |
Show more